Eplerenone: A review of its use in patients with chronic systolic heart failure and mild symptoms

Drugs

Volumn 73, Issue 13, 2013, Pages 1451-1462

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; AMIFOSTINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ERYTHROMYCIN; GLUCOCORTICOID; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; MINERALOCORTICOID RECEPTOR; NELFINAVIR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; RITONAVIR; SAQUINAVIR; SPIRONOLACTONE; TACROLIMUS; TETRACOSACTIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; UNINDEXED DRUG;

AREA UNDER THE CURVE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; FOLLOW UP; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MULTIPLE DRUG DOSE; OUTCOME ASSESSMENT; PLASMA PROTEIN BINDING; POTASSIUM BLOOD LEVEL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; SURVIVAL; SYSTOLIC HEART FAILURE;

ADULT; DEVICE APPROVAL; DRUG INTERACTIONS; EUROPEAN UNION; HEART FAILURE, SYSTOLIC; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE;

EID: 84884618648     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0098-z     Document Type: Review

References (72)

1. Ma TK, Kam KK, Yan BP, et al. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273-92.
2. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107(19):2512-8.
3. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5(1 Suppl):S7-10.
4. Nappi JM, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag. 2011;7:353-63.
5. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21(6 Pt 2):929-33.
6. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37(3):845-50.
7. Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114(24):2604-10.
8. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006;114(24):2572-4.
9. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82(5):1730-6.
10. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10(12 Pt 1):1326-34.
11. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101(6):594-7.
12. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3):457-65.
13. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100(10):1056-64.
14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.
15. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10(1):23-9.
16. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153-8.
17. Pfizer Ltd. Inspra (eplerenone): UK summary of product characteristics. 2012. http://www.medicines.org.uk/EMC/medicine/16746/SPC/ Inspra+25mg+%26+50+mg+film-coated+tablets/. Accessed 1 Mar 2013.
18. Pfizer Inc. Inspra (eplerenone) tablets: US prescribing information. 2012. http://labeling.pfizer.com/ShowLabeling.aspx?id=599. Accessed 3 Apr 2013.
19. Keating GM, Plosker GL. Eplerenone: a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. Drugs. 2004;64(23):2689-707.
20. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93(1):69-76.
21. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42(9):1666-73.
22. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143(12):4828-36.
23. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283(5):H1802-10.
24. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106(23):2967-72.
25. Rastogi S, Mishra S, Zaca V, et al. Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiovasc Drugs Ther. 2007;21(6):415-22.
26. De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst. 2006;7(1):40-6.
27. De Mello WC, Gerena Y. Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart: on the presence of an intracrine renin angiotensin aldosterone system. Regul Pept. 2008;151(1-3):54-60.
28. Schafer A, Fraccarollo D, Hildemann SK, et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res. 2003;58(3):655-62.
29. Schafer A, Fraccarollo D, Hildemann S, et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost. 2003;89(6):1024-30.
30. Jung C, Florvaag A, Oberle V, et al. Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst. 2012;13(3):401-6.
31. Stewart RAH, Kerr AJ, Cowan BR, et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J. 2008;156(2):348-55.
32. Satoh M, Ishikawa Y, Minami Y, et al. Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure. Heart. 2006;92(7):979-80.
33. Sudano I, Flammer AJ, Roas S, et al. Effect of low dose eplerenone on endothelial function in patients with stable coronary artery disease [abstract no. P2609]. Eur Heart J. 2012;33 Suppl 1:442.
34. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circulation. 2010;3(3):347-53.
35. 1c levels in patients with chronic heart failure. Am Heart J. 2010;160(5):915-21.
36. Deedwania P, Pitt B, Desai R, et al. Aldosterone antagonism with eplerenone does not adversely affect plasma glucose levels in patients with diabetes mellitus: findings from a post hoc analysis of the EPHESUS trial [abstract no. P2456]. Eur Heart J. 2010;31 Suppl 1:423-4.
37. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240(2):650-6.
38. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217(1-2):27-31.
39. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709-16.
40. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutical review(s) [NDA 21-437]. 2003. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2002/21-437-Inspra-BioPharmr-P3.pdf. Accessed 22 Apr 2013.
41. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review (21-437/S-002). 2003. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2003/21-437S002-Inspra-BioPharmr.pdf. Accessed 22 Apr 2013.
42. Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003;31(11):1448-55.
43. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
44. Pitt B, McMurray JJ, Swedberg K, et al. The incidence and risk associated with serum potassium <4.0 mmol/L in patients with heart failure and a reduced left ventricular ejection fraction (HF-REF): results from the EMPHASIS-HF trial [abstract no. 17379 plus poster]. American Heart Association Scientific Session; 3-7 Nov 2012; Los Angeles (CA).
45. Zannad F, McMurray JJV, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12(6):617-22.
46. Krum H, Shi H, Pitt B, et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF Study. Circ Heart Fail. 2013. doi: 10.1161/CIRCHEARTFAILURE.112.000173.
47. Kjeldsen K. Hypokalemia and sudden cardiac death. Exp Clin Cardiol. 2010;15(4):e96-9.
48. Cleland JG, Dargie HJ, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J. 1987;58(6):572-82.
49. Neuberger HR, Mewis C, van Veldhuisen DJ, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J. 2007;28(21):2568-77.
50. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.
51. Lendeckel U, Dobrev D, Goette A. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br J Pharmacol. 2010;159(8):1581-3.
52. Tsai CT, Chiang FT, Tseng CD, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol. 2010;55(8):758-70.
53. Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol. 2010;159(8):1584-94.
54. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832-9.
55. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28(4):457-62.
56. Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603.
57. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;29(10):1224-40.
58. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201-7.
59. Preiss D, van Veldhuisen DJ, Sattar N, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012;14(8):909-15.
60. Rogers JK, McMurray JJV, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126(19):2317-23.
61. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [erratum appears in N Engl J Med. 2003;348(22):2271]. N Engl J Med. 2003;348(14):1309-21.
62. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [errata appear in Eur Heart J. 2010;31(5):624 and Eur Heart J. 2010;12(4):416]. Eur Heart J. 2008;29(19):2388-442.
63. Sica DA. The risks and benefits of aldosterone antagonists. Curr Heart Fail Rep. 2005;2(2):65-71.
64. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121(7):934-9.
65. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847.
66. Armstrong PW. Aldosterone antagonists-last man standing? N Engl J Med. 2011;364(1):79-80.
67. Lund LH, Svennblad B, Melhus H, et al. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. Circ Heart Fail. 2013;6(2):174-83.
68. Pitt B, Zannad F. Eplerenone: is it time to add this drug to current heart failure therapy? Ther Adv Chronic Dis. 2012;3(1):5-9.
69. Davies JI, Band M, Morris A, et al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1687-94.
70. Pharmacia Ltd. Aldactone: UK summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/9136/SPC/Aldactone+25mg+Tablets/. Accessed 8 May 2013.
71. Struthers AD, Unger T. Physiology of aldosterone and pharmacology of aldosterone blockers. 2011;13 Suppl B:B27-30.
72. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013. doi: 10.1093/eurheartj/ eht187.